AMPH: Robust R&D and a proprietary-focused pipeline drive growth, anchored by BAQSIMI® and Primatene MIST®
A fully integrated model and strong R&D investment have driven robust revenue and margin growth, with a pipeline shifting toward proprietary and biosimilar products. Key assets like BAQSIMI® and Primatene MIST® anchor commercial performance, while new launches and expanded global reach are set to f…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.